AEON Biopharma, Inc.

AEON Biopharma, Inc. is a biopharmaceutical company focused on developing its lead drug candidate, ABP-450, as a biosimilar to Botox for debilitating medical conditions. The company advances ABP-450 through the biosimilar regulatory pathway exclusively for therapeutic indications rather than cosmetic uses. ABP-450 is a botulinum neurotoxin complex intended to treat disorders such as cervical dystonia, spasticity, and chronic migraine. AEON plans to market and distribute the treatment directly to healthcare providers, physicians, and health systems operating within physician-administered medical environments.

The company holds exclusive development and distribution rights for therapeutic uses of ABP-450 across the United States, Canada, the European Union, the United Kingdom, and select other international territories. The underlying drug substance is manufactured at a dedicated facility in South Korea by Daewoong Pharmaceutical. AEON conducts its operations primarily in the United States, where it concentrates its commercialization and regulatory activities, though the provided text does not disclose the specific city or state of its corporate headquarters.

Summary of the business section of AEON Biopharma's latest annual report, written by StockData.

“As of December 31, 2025, we had eight employees.”